Primary regional disparities in clinical characteristics, treatments, and outcomes of a typically designed study of valvular heart disease at 46 tertiary hospitals in China: Insights from the China-VHD Study.
10.1097/CM9.0000000000003570
- Author:
Xiangming HU
1
;
Yunqing YE
1
;
Zhe LI
1
;
Qingrong LIU
1
;
Zhenyan ZHAO
1
;
Zheng ZHOU
1
;
Weiwei WANG
1
;
Zikai YU
1
;
Haitong ZHANG
1
;
Zhenya DUAN
1
;
Bincheng WANG
1
;
Bin ZHANG
1
;
Junxing LV
1
;
Shuai GUO
1
;
Yanyan ZHAO
2
;
Runlin GAO
1
;
Haiyan XU
1
;
Yongjian WU
1
Author Information
1. Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
2. Medical Research & Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
- Collective Name:China-VHD Study Collaborators
- Publication Type:Multicenter Study
- Keywords:
China;
Etiology;
Outcome;
Regional difference;
Treatment;
Valvular heart disease
- MeSH:
Aged;
Female;
Humans;
Male;
Middle Aged;
China/epidemiology*;
Heart Valve Diseases/therapy*;
Kaplan-Meier Estimate;
Tertiary Care Centers;
Treatment Outcome
- From:
Chinese Medical Journal
2025;138(8):937-946
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Valvular heart disease (VHD) has become increasingly common with the aging in China. This study aimed to evaluate regional differences in the clinical features, management strategies, and outcomes of patients with VHD across different regions in China.
METHODS:Data were collected from the China-VHD Study. From April 2018 to June 2018, 12,347 patients who presented with moderate or severe native VHD with a median of 2 years of follow-up from 46 centers at certified tertiary hospitals across 31 provinces, autonomous regions, and municipalities in Chinese mainland were included in this study. According to the locations of the research centers, patients were divided into five regional groups: eastern, southern, western, northern, and central China. The clinical features of VHD patients were compared among the five geographical regions. The primary outcome was all-cause mortality or rehospitalization for heart failure. Kaplan-Meier survival analysis was used to compare the cumulative incidence rate.
RESULTS:Among the enrolled patients (mean age, 61.96 years; 6877 [55.70%] male), multiple VHD was the most frequent type (4042, 32.74%), which was mainly found in eastern China, followed by isolated mitral regurgitation (3044, 24.65%), which was mainly found in northern China. The etiology of VHD varied significantly across different regions of China. The overall rate of valve interventions was 32.67% (4008/12,268), with the highest rate in southern China at 48.46% (205/423). In terms of procedure, the proportion of transcatheter valve intervention was relatively low compared to that of surgical treatment. Patients with VHD in western China had the highest incidence of all-cause mortality or rehospitalization for heart failure. Valve intervention significantly improved the outcome of patients with VHD in all five regions (all P <0.05).
CONCLUSIONS:This study revealed that patients with VHD in China are characterized by significant geographic disparities in clinical features, treatment, and clinical outcomes. Targeted efforts are needed to improve the management and prognosis of patients with VHD in China according to differences in geographical characteristics.
REGISTRATION:ClinicalTrials.gov , NCT03484806.
